Drug Profile
Research programme: small-molecule therapeutics - Elicio Therapeutics
Alternative Names: ANG 3586; ANG-3067; ANG-3281; ANG-3407; ANG-4011; ANG-4021Latest Information Update: 07 Jun 2023
Price :
$50
*
At a glance
- Originator Angion Biomedica
- Developer Elicio Therapeutics
- Class Antifibrotics; Antineoplastics; Small molecules
- Mechanism of Action Peptide hormone stimulants; Retinoic acid receptor modulators; Retinoid X receptor modulators; Steroid 17-alpha-hydroxylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Fibrosis; Kidney disorders; Prostate cancer